Firm
The variety of winners demonstrates that the UPC is now a core benchmark rather than an experimental consideration, while junior lawyers are becoming more deeply involved in key work
Sheppard, which has hired 14 IP partners in the last 12 months, has cited client demand for expert counsel in SEP, ITC, and district court disputes
Tingxi Huo joins our ‘Five minutes with’ series to discuss boosting the value of clients’ IP and the importance of reflection
Hefty legal teams assembled for a three-day hearing in what was the court’s first foray into SEPs since Unwired Planet v Huawei
Sponsored
Sponsored
-
Sponsored by Tilleke & GibbinsSon Thai Hoang and Linh Thi Mai Nguyen of Tilleke & Gibbins highlight the strict stance taken by the Intellectual Property Office of Vietnam on assignments conflicting with trade names and join the calls for clearer guidance -
Sponsored by Tilleke & GibbinsThe Central Intellectual Property and International Trade Court has confirmed that a design’s overall appearance should be considered when determining its eligibility for patent protection, report Nuttaphol Arammuang and Tanapong Pongburanakit of Tilleke & Gibbins
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law reports on a decision that should provide improved guidance in determining whether patents or approved drugs are eligible for a patent term extension in South Korea
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Shipra Alisha Philip of RNA, Technology and IP Attorneys analyse how a US ruling could affect digital libraries, e-book licensing, and public access to knowledge in India
-
Sponsored by Bird & BirdEmilia Zalewska and Andrzej Stelmachowski of Bird & Bird provide insights into two matters considered by the Unified Patent Court and a Polish court concerning the imminent infringement of patent rights in the pharmaceutical industry
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
